Article
- Author:
- Jonathan M. Meyer, MD
Publish date: March 1, 2022
Among patients with bipolar I or II disorder (BD I or II), major depressive episodes represent the predominant mood state when not euthymic, and ar...
Article
- Author:
- Jonathan M. Meyer, MD
Publish date: February 3, 2020
Lumateperone is a novel oral antipsychotic approved for the treatment of adult patients with schizophrenia.
Article
- Author:
- Jonathan M. Meyer, MD
Publish date: December 1, 2018
RBP-7000 (Perseris) is the second long-acting injectable form of risperidone
approved in the United States.
Article
- Author:
- Jonathan M. Meyer, MD
Publish date: October 26, 2018
New long-acting injectable formulation simplifies the initiation regimen.
Article
- Author:
- Jonathan M. Meyer, MD
Publish date: January 2, 2018
Use these strategies to maximize efficacy and minimize adverse effects when prescribing a monoamine oxidase inhibitor. Second of 2 parts.
Article
- Author:
- Jonathan M. Meyer, MD
Publish date: December 1, 2017
A better understanding of the risks can lead to increased use of these highly effective agents. First of 2 parts.
Video
- Author:
- Jonathan M. Meyer, MD
Publish date: December 1, 2017
Jonathan M. Meyer, MD, discusses what to tell patients about diet and monoamine oxidase inhibitors.
Article
- Author:
- Jonathan M. Meyer, MD
Publish date: October 1, 2017
Compared with first-generation antipsychotics, second-generation antipsychotics (SGAs) have a lower risk for extrapyramidal symptoms. Yet tardive d...
Article
- Author:
- Jonathan M. Meyer, MD
Publish date: May 1, 2017
Despite improvements in the tolerability of antipsychotic medications, the development of tardive dyskinesia (TD) still is a significant area of co...
Audio
- Author:
- Jonathan M. Meyer, MD
Publish date: March 1, 2017
Article
- Author:
- Jonathan M. Meyer, MD
Publish date: September 1, 2016
Pimavanserin is a potent 5-HT2A inverse agonist and 5-HT2C inverse agonist, with 5-fold greater affinity for the 5-HT2A receptor.1 Altho...
Audio
- Author:
- Jonathan M. Meyer, MD
Publish date: June 29, 2016
News
- Author:
- Jonathan M. Meyer, MD
Publish date: October 26, 2015
The literature on plasma levels of antipsychotics documents the difficulties faced in establishing therapeutic ranges with the predictive power of ...
News
- Author:
- Jonathan M. Meyer, MD
Publish date: December 23, 2014
Stay on course with MOC by gaining close knowledge of its component requirements
News
- Author:
- Jonathan M. Meyer, MD
Publish date: November 24, 2014
The MOC process is manageable, but you need to be conversant with its elements
